CryoPort, Inc. (NASDAQ:CYRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $11.00.

Several equities research analysts recently issued reports on CYRX shares. Roth Mkm reaffirmed a "buy" rating and set a $15.00 price target on shares of CryoPort in a report on Tuesday, April 1st. Guggenheim reaffirmed a "buy" rating and set a $10.00 target price on shares of CryoPort in a research note on Wednesday, April 16th. UBS Group upped their price target on shares of CryoPort from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of CryoPort in a report on Thursday, May 8th. Finally, Morgan Stanley reduced their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th.

Insider Activity at CryoPort

In related news, insider Edward J. Zecchini sold 51,500 shares of CryoPort stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $6.84, for a total value of $352,260.00. Following the transaction, the insider now directly owns 90,411 shares of the company's stock, valued at $618,411.24. The trade was a 36.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jerrell Shelton sold 151,304 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $6.81, for a total transaction of $1,030,380.24. Following the sale, the chief executive officer now directly owns 912,419 shares of the company's stock, valued at $6,213,573.39. This represents a 14.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold 420,054 shares of company stock worth $2,833,558 over the last three months. Company insiders own 10.10% of the company's stock.

Institutional Investors Weigh In On CryoPort

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers grew its stake in CryoPort by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after purchasing an additional 1,764 shares during the period. Olympiad Research LP bought a new position in shares of CryoPort during the 4th quarter worth approximately $103,000. Heritage Investors Management Corp acquired a new stake in shares of CryoPort during the 4th quarter worth approximately $122,000. AlphaQuest LLC grew its position in shares of CryoPort by 81.3% during the 4th quarter. AlphaQuest LLC now owns 52,714 shares of the company's stock worth $410,000 after buying an additional 23,631 shares during the period. Finally, Thrivent Financial for Lutherans bought a new stake in shares of CryoPort in the 4th quarter valued at $299,000. 92.90% of the stock is owned by institutional investors.

CryoPort Price Performance

CryoPort stock traded up $0.74 during trading hours on Friday, reaching $7.30. 723,676 shares of the stock were exchanged, compared to its average volume of 530,747. The stock has a 50 day moving average of $6.22 and a two-hundred day moving average of $6.69. The company has a market cap of $366.02 million, a P/E ratio of -3.12 and a beta of 1.85. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51. CryoPort has a twelve month low of $4.58 and a twelve month high of $9.78.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. The business had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. Equities analysts expect that CryoPort will post -0.99 EPS for the current fiscal year.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.